Denali Therapeutics Inc (DNLI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has a cash flow conversion efficiency ratio of -0.116x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-97.00 Million) by net assets ($835.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Denali Therapeutics Inc for the company's overall valuation and market capitalisation.
Denali Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Denali Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Denali Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Denali Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Denali Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shihlin Electric & Engineering Corp
TW:1503
|
0.028x |
|
Beiqi Foton Motor Co Ltd
SHG:600166
|
-0.010x |
|
Samsung Card Co. Ltd.
KO:029780
|
0.024x |
|
Kirloskar Oil Engines Limited
NSE:KIRLOSENG
|
0.097x |
|
JA Solar Technology Co Ltd
SHE:002459
|
0.010x |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
0.017x |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
0.051x |
|
Assured Guaranty Ltd
NYSE:AGO
|
0.034x |
Annual Cash Flow Conversion Efficiency for Denali Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Denali Therapeutics Inc from 2015 to 2025. View Denali Therapeutics Inc (DNLI) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.01 Billion | $-412.60 Million | -0.407x | -43.94% |
| 2024-12-31 | $1.23 Billion | $-347.69 Million | -0.283x | +18.57% |
| 2023-12-31 | $1.03 Billion | $-357.99 Million | -0.347x | -47.92% |
| 2022-12-31 | $1.04 Billion | $-244.72 Million | -0.235x | -6.87% |
| 2021-12-31 | $962.29 Million | $-211.39 Million | -0.220x | -160.73% |
| 2020-12-31 | $1.15 Billion | $416.15 Million | 0.362x | +194.23% |
| 2019-12-31 | $394.89 Million | $-151.58 Million | -0.384x | -518.83% |
| 2018-12-31 | $546.85 Million | $50.12 Million | 0.092x | +155.70% |
| 2017-12-31 | $465.80 Million | $-76.64 Million | -0.165x | +42.13% |
| 2016-12-31 | $254.52 Million | $-72.36 Million | -0.284x | -129.53% |
| 2015-12-31 | $-15.63 Million | $-15.05 Million | 0.963x | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pr… Read more